세계의 희귀질환 임상시험 시장 보고서(2025년)

Rare disease clinical trials are carefully structured medical studies aimed at assessing the safety, efficacy, and potential treatments for rare or orphan diseases that affect a small number of patients. These trials are designed to generate essential clinical evidence to support regulatory approval and enhance patient outcomes. They often face unique challenges, including limited patient availability, specialized trial protocols, and higher costs compared to trials for more common conditions.

The primary phases of rare disease clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials are early-stage studies that evaluate safety, dosage, and preliminary efficacy of investigational therapies in patients with rare diseases. Therapeutic areas covered include oncology, cardiovascular disorders, neurological disorders, infectious diseases, genetic disorders, autoimmune and inflammatory conditions, hematologic disorders, musculoskeletal disorders, and others. Study designs include interventional, observational, and expanded access trials, serving end users such as pharmaceutical companies, biotechnology firms, research institutions, and other stakeholders.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare disease clinical trials market research report is one of a series of new reports from The Business Research Company that provides rare disease clinical trials market statistics, including the rare disease clinical trials industry global market size, regional shares, competitors with the rare disease clinical trials market share, detailed rare disease clinical trials market segments, market trends, and opportunities, and any further data you may need to thrive in the rare disease clinical trials industry. This rare disease clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare disease clinical trials market size has grown rapidly in recent years. It will grow from $12.06 billion in 2024 to $13.30 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth observed during the historic period can be linked to increasing awareness of genetic disorders among healthcare providers, higher demand for specialized patient monitoring during trials, growing development of personalized medicine approaches, wider adoption of patient-centric trial methodologies, and rising need for global multi-center clinical studies.

The rare disease clinical trials market size is expected to see rapid growth in the next few years. It will grow to $19.45 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth projected for the forecast period can be attributed to a rise in the number of rare disease therapies entering clinical trials, greater regulatory support for orphan drug approvals, expansion of disease-specific patient registries and databases, increasing cross-border clinical trials and multi-center studies, and enhanced funding initiatives for rare disease research infrastructure. Key trends during the forecast period include expanded use of decentralized trial models, innovations in patient recruitment strategies, integration of real-world evidence into trial designs, development of precision medicine approaches, and broader adoption of digital health technologies.

The growth of the rare disease clinical trials market is expected to be driven by the rise of personalized medicine. This approach involves tailoring medical treatments to the individual characteristics of each patient, including their genetics, lifestyle, and environment. Personalized medicine is gaining momentum due to its ability to improve treatment outcomes by offering therapies designed to be more effective and safer for each patient. Rare disease clinical trials play a vital role in advancing this field by providing insights that guide the creation of targeted therapies based on a patient's unique genetic and molecular profile. For example, the Personalized Medicine Coalition (PMC) reported that personalized medicines accounted for 34% of FDA approvals in 2022 and rose to 38% in 2023. As a result, the increased adoption of personalized medicine is driving the growth of clinical trials for rare diseases.

Leading companies in the rare disease clinical trials market are emphasizing innovation by adopting a client-centric model, which focuses on meeting the specific needs and preferences of biotech and pharmaceutical clients. This approach allows for the development of personalized clinical trial solutions, improving patient engagement and accelerating the creation of therapies for rare conditions. A notable example is Evestia Clinical Limited, which was introduced as the new brand identity for EMAS Pharma in March 2025. This rebranding signals the company's strategic shift towards global expansion and its commitment to advancing therapies for rare diseases. Evestia Clinical is focused on offering personalized clinical trial solutions that address the unique challenges of rare conditions, making this a core aspect of its service offering and brand identity.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma, a French company specializing in rare endocrine disease therapies. The acquisition, the financial details of which were not disclosed, expands AstraZeneca's portfolio in rare disease treatments and supports its commitment to addressing unmet medical needs. Amolyt Pharma focuses on the development of therapies for rare endocrine disorders and the management of related clinical trials.

Major players in the rare disease clinical trials market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, Moderna Inc., Charles River Laboratories International Inc., Parexel International Corporation, Revvity Inc., Sarepta Therapeutics Inc., TFS HealthScience, Inventiva S.A., Tonix Pharmaceuticals Holding Corp., SpringWorks Therapeutics Inc., OrphAI Therapeutics Inc., BBCR Consulting LLC, and Credevo Inc.

North America was the largest region in the rare disease clinical trials market in 2024. The regions covered in rare disease clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare disease clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare disease clinical trials market includes revenues earned by entities through clinical trial design and protocol development, pharmacovigilance and safety services, and laboratory and biomarker services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Disease Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare disease clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare disease clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare disease clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
• 2) By Therapeutic Area: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Disease; Genetic Disorders; Autoimmune And Inflammation; Hematologic Disorders; Musculoskeletal Disorders; Other Therapeutic Areas
• 3) By Study Design: Interventional; Observational; Expanded Access
• 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
• Subsegments:
• 1) By Phase I: First In Human Trials; Dose Escalation Studies; Safety And Tolerability Studies
• 2) By Phase II: Proof Of Concept Studies; Dose Response Studies; Efficacy And Safety Studies
• 3) By Phase III: Randomized Controlled Trials; Comparative Effectiveness Studies; Large Scale Multicenter Trials
• 4) By Phase IV: Post Marketing Surveillance; Long Term Safety Studies; Real World Evidence Studies
• Companies Mentioned: F. Hoffmann-La Roche AG; Pfizer Inc.; Novartis AG; AstraZeneca plc; Takeda Pharmaceutical Company Limited; IQVIA Holdings Inc.; Laboratory Corporation of America Holdings; ICON plc; Moderna Inc.; Charles River Laboratories International Inc.; Parexel International Corporation; Revvity Inc.; Sarepta Therapeutics Inc.; TFS HealthScience; Inventiva S.A.; Tonix Pharmaceuticals Holding Corp.; SpringWorks Therapeutics Inc.; OrphAI Therapeutics Inc.; BBCR Consulting LLC; Credevo Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Disease Clinical Trials Market Characteristics

3. Rare Disease Clinical Trials Market Trends And Strategies

4. Rare Disease Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Disease Clinical Trials Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rare Disease Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rare Disease Clinical Trials Market Growth Rate Analysis
• 5.4. Global Rare Disease Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rare Disease Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rare Disease Clinical Trials Total Addressable Market (TAM)

6. Rare Disease Clinical Trials Market Segmentation

• 6.1. Global Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiovascular Disorders
• Neurological Disorders
• Infectious Disease
• Genetic Disorders
• Autoimmune And Inflammation
• Hematologic Disorders
• Musculoskeletal Disorders
• Other Therapeutic Areas
• 6.3. Global Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interventional
• Observational
• Expanded Access
• 6.4. Global Rare Disease Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Other End-Users
• 6.5. Global Rare Disease Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First In Human Trials
• Dose Escalation Studies
• Safety And Tolerability Studies
• 6.6. Global Rare Disease Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proof Of Concept Studies
• Dose Response Studies
• Efficacy And Safety Studies
• 6.7. Global Rare Disease Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Randomized Controlled Trials
• Comparative Effectiveness Studies
• Large Scale Multicenter Trials
• 6.8. Global Rare Disease Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post Marketing Surveillance
• Long Term Safety Studies
• Real World Evidence Studies

7. Rare Disease Clinical Trials Market Regional And Country Analysis

• 7.1. Global Rare Disease Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rare Disease Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Disease Clinical Trials Market

• 8.1. Asia-Pacific Rare Disease Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Disease Clinical Trials Market

• 9.1. China Rare Disease Clinical Trials Market Overview
• 9.2. China Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Disease Clinical Trials Market

• 10.1. India Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Disease Clinical Trials Market

• 11.1. Japan Rare Disease Clinical Trials Market Overview
• 11.2. Japan Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Disease Clinical Trials Market

• 12.1. Australia Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Disease Clinical Trials Market

• 13.1. Indonesia Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Disease Clinical Trials Market

• 14.1. South Korea Rare Disease Clinical Trials Market Overview
• 14.2. South Korea Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Disease Clinical Trials Market

• 15.1. Western Europe Rare Disease Clinical Trials Market Overview
• 15.2. Western Europe Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Disease Clinical Trials Market

• 16.1. UK Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Disease Clinical Trials Market

• 17.1. Germany Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Disease Clinical Trials Market

• 18.1. France Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Disease Clinical Trials Market

• 19.1. Italy Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Disease Clinical Trials Market

• 20.1. Spain Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Disease Clinical Trials Market

• 21.1. Eastern Europe Rare Disease Clinical Trials Market Overview
• 21.2. Eastern Europe Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Disease Clinical Trials Market

• 22.1. Russia Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Disease Clinical Trials Market

• 23.1. North America Rare Disease Clinical Trials Market Overview
• 23.2. North America Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Disease Clinical Trials Market

• 24.1. USA Rare Disease Clinical Trials Market Overview
• 24.2. USA Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Disease Clinical Trials Market

• 25.1. Canada Rare Disease Clinical Trials Market Overview
• 25.2. Canada Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Disease Clinical Trials Market

• 26.1. South America Rare Disease Clinical Trials Market Overview
• 26.2. South America Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Disease Clinical Trials Market

• 27.1. Brazil Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Disease Clinical Trials Market

• 28.1. Middle East Rare Disease Clinical Trials Market Overview
• 28.2. Middle East Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Disease Clinical Trials Market

• 29.1. Africa Rare Disease Clinical Trials Market Overview
• 29.2. Africa Rare Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rare Disease Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rare Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Disease Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. Rare Disease Clinical Trials Market Competitive Landscape
• 30.2. Rare Disease Clinical Trials Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Rare Disease Clinical Trials Market Other Major And Innovative Companies

• 31.1. IQVIA Holdings Inc.
• 31.2. Laboratory Corporation of America Holdings
• 31.3. ICON plc
• 31.4. Moderna Inc.
• 31.5. Charles River Laboratories International Inc.
• 31.6. Parexel International Corporation
• 31.7. Revvity Inc.
• 31.8. Sarepta Therapeutics Inc.
• 31.9. TFS HealthScience
• 31.10. Inventiva S.A.
• 31.11. Tonix Pharmaceuticals Holding Corp.
• 31.12. SpringWorks Therapeutics Inc.
• 31.13. OrphAI Therapeutics Inc.
• 31.14. BBCR Consulting LLC
• 31.15. Credevo Inc.

32. Global Rare Disease Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Disease Clinical Trials Market

34. Recent Developments In The Rare Disease Clinical Trials Market

35. Rare Disease Clinical Trials Market High Potential Countries, Segments and Strategies

• 35.1 Rare Disease Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rare Disease Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rare Disease Clinical Trials Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer